Tumors of the Central Nervous System in Children and Adolescents

被引:30
|
作者
Fruehwald, Michael C. [1 ]
Rutkowski, Stefan [2 ]
机构
[1] I Klin Kinder & Jugendliche, Klinikum Augsburg, D-86156 Augsburg, Germany
[2] Univ Klinikum Hamburg Eppendorf, Klin Padiatr Hamatol & Onkol, Hamburg, Germany
来源
DEUTSCHES ARZTEBLATT INTERNATIONAL | 2011年 / 108卷 / 22期
关键词
TRIALS HIT 88/89; CHILDHOOD; MEDULLOBLASTOMA; CHEMOTHERAPY; RADIOTHERAPY; GLIOMAS;
D O I
10.3238/arztebl.2011.0390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Multimodal treatment approaches for children with tumors of the central nervous system (CNS) have markedly contributed to improved survival. Before 1970, the survival rate among children with medulloblastoma, the most common malignant CNS tumor in children, was about 20%. At present, in contrast, cure can be achieved in more than 75% of children with a favorable constellation of risk factors. In this review article for clinicians, we give an overview of the current understanding of the pathology, presenting manifestations, early diagnosis, and treatment of CNS tumors in children and adolescents. Methods: We report the research findings of the German Treatment Network "HIT" and selectively review the pertinent literature. Results: Treatment-optimizing clinical trials have improved survival from all types of CNS tumors in children and adolescents. Biological features of the tumors now serve as the basis for improved stratification for multimodal, risk-adapted treatment. Targeted biological strategies are being developed. Difficulties remain, however, in the care of infants with CNS tumors and in the treatment of metastatic disease, tumors of certain histological types, and tumors in certain anatomical sites. Many of the affected children suffer from late effects of their disease and its treatment that can irreversibly impair their development. Conclusion: Children with a suspected or confirmed diagnosis of brain tumor should be referred early to a center with the relevant experience. Standardized diagnostic and therapeutic methods have markedly improved the chance of cure. Current research on molecular signaling pathways seems likely to lead to the development of new treatments, particularly for tumors currently associated with lower rates of survival. The long-term side effects of treatment must be systematically monitored so that they can be avoided in future, and so that appropriate support measures can be provided to the affected children.
引用
收藏
页码:390 / U25
页数:10
相关论文
共 50 条
  • [41] Molecular pathology of tumors of the central nervous system
    Kristensen, B. W.
    Priesterbach-Ackley, L. P.
    Petersen, J. K.
    Wesseling, P.
    ANNALS OF ONCOLOGY, 2019, 30 (08) : 1265 - 1278
  • [42] Genetics of pediatric central nervous system tumors
    Biegel, JA
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (06) : 492 - 501
  • [43] Pharmacotherapy for adults with tumors of the central nervous system
    Schor, Nina F.
    PHARMACOLOGY & THERAPEUTICS, 2009, 121 (03) : 253 - 264
  • [44] Management of primary central nervous system lymphoma in children
    Giulino-Roth, Lisa
    Abla, Oussama
    Batchelor, Tracy T.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 386 - 389
  • [45] Health disparities and impact on outcomes in children with primary central nervous system solid tumors
    Austin, Mary T.
    Hamilton, Emma
    Zebda, Denna
    Hoang Nguyen
    Eberth, Jan M.
    Chang, Yuchia
    Elting, Linda S.
    Sandberg, David I.
    JOURNAL OF NEUROSURGERY-PEDIATRICS, 2016, 18 (05) : 585 - 593
  • [46] Soft tissue sarcomas and central nervous system tumors in children with neurofibromatosis type 1
    Emre Cecen
    Dilek Ince
    Kamer Mutafoglu Uysal
    Erdener Ozer
    Riza Cetingoz
    Ali Aykan Ozguven
    Handan Cakmakci
    Faik Sarialioglu
    Nur Olgun
    Child's Nervous System, 2011, 27 : 1885 - 1893
  • [47] Palliative care for children with central nervous system tumors: results of a Spanish multicenter study
    Perez-Torres Lobato, Maria
    Navarro-Marchena, Lucia
    de Noriega, Inigo
    Morey Olive, Miriam
    Solano-Paez, Palma
    Rubio Perez, Eloisa
    Garrido Colino, Carmen
    Garcia Abos, Miriam
    Tallon Garcia, Maria
    Huidobro Labarga, Beatriz
    Portugal Rodriguez, Raquel
    Lopez Ibor, Blanca
    Lassaletta, Alvaro
    Morgenstern Isaak, Andres
    Cruz Martinez, Ofelia
    Valero Arrese, Lorena
    Llort Sales, Anna
    Gros Subias, Luis
    Marquez Vega, Catalina
    Moreno, Lucas
    Quiroga-Cantero, Eduardo
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (03) : 786 - 795
  • [48] Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors
    Buesker, Soeren
    Jaeger, Walter
    Poschner, Stefan
    Mayr, Lisa
    Al Jalali, Valentin
    Gojo, Johannes
    Azizi, Amedeo A.
    Ullah, Sami
    Bilal, Muhammad
    El Tabei, Lobna
    Fuhr, Uwe
    Peyrl, Andreas
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (05) : 617 - 627
  • [49] Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections
    Wright, Karen D.
    Panetta, John C.
    Onar-Thomas, Arzu
    Reddick, Wilburn E.
    Patay, Zoltan
    Qaddoumi, Ibrahim
    Broniscer, Alberto
    Robinson, Giles
    Boop, Frederick A.
    Klimo, Paul, Jr.
    Ward, Deborah
    Gajjar, Amar
    Stewart, Clinton F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 27 - 35
  • [50] Necrosis After Craniospinal Irradiation: Results From a Prospective Series of Children With Central Nervous System Embryonal Tumors
    Murphy, Erin S.
    Merchant, Thomas E.
    Wu, Shengjie
    Xiong, Xiaoping
    Lukose, Renin
    Wright, Karen D.
    Qaddoumi, Ibrahim
    Armstrong, Gregory T.
    Broniscer, Alberto
    Gajjar, Amar
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (05): : E655 - E660